Karapanagiotou Eleni M, Syrigos Kostas, Saif Muhammad Wasif
Athens Medical School, Medical Oncology, Athens, Greece.
Expert Opin Investig Drugs. 2009 Feb;18(2):161-74. doi: 10.1517/13543780802715792.
Heat shock proteins (HSP) play an essential role as molecular chaperones by assisting correct holding and folding in human cells. At the same time they present implications in tumor cell proliferation, differentiation, matrix invasion, angiogenesis, metastasis and cell death. They also possess the ability to present tumor molecules to the immune system and elicit an immune response. New agents targeting HSP, as anticancer treatment, are under clinical evaluation.
The aim of this review is to explore the role of HSP90 inhibitors as anticancer agents as well as to evaluate the benefit from the use of autologous HSP vaccines in both the adjuvant setting and first-line treatment.
The latest evidence regarding the use of geldanamycin analogues or newer water-soluble and synthetics molecules that inhibit the binding of HSP90 to client proteins was reviewed. Immunization using tumor-derived HSP in several cancer types was also evaluated.
HSP90 inhibitors represent a promising therapeutic option although further evaluation in larger clinical trials is needed. On the other hand, HSP vaccination has already an established role in our armory against cancer.
热休克蛋白（HSP）作为分子伴侣，在协助人类细胞中蛋白质的正确折叠和维持方面发挥着重要作用。同时，它们在肿瘤细胞的增殖、分化、基质侵袭、血管生成、转移和细胞死亡中也具有重要意义。它们还具备将肿瘤分子呈递给免疫系统并引发免疫反应的能力。作为抗癌治疗手段，针对热休克蛋白的新型药物正在进行临床评估。
本综述旨在探讨HSP90抑制剂作为抗癌药物的作用，并评估在辅助治疗和一线治疗中使用自体HSP疫苗的益处。
回顾了有关使用格尔德霉素类似物或抑制HSP90与客户蛋白结合的新型水溶性和合成分子的最新证据。还评估了在几种癌症类型中使用肿瘤来源的HSP进行免疫接种的情况。
HSP90抑制剂是一种有前景的治疗选择，不过仍需要在更大规模的临床试验中进行进一步评估。另一方面，HSP疫苗在我们对抗癌症的武器库中已经确立了其作用。
